Gyre Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
In This Article:
Gyre Therapeutics (NASDAQ:GYRE) Full Year 2024 Results
Key Financial Results
-
Revenue: US$105.8m (down 6.8% from FY 2023).
-
Net income: US$12.1m (up from US$92.9m loss in FY 2023).
-
Profit margin: 11% (up from net loss in FY 2023). The move to profitability was driven by lower expenses.
-
EPS: US$0.14 (up from US$1.41 loss in FY 2023).
GYRE Products In Clinical Trials
-
Phase I: 2.
-
Phase II: 1.
-
Phase III: 2.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Gyre Therapeutics Revenues Beat Expectations, EPS Falls Short
Revenue exceeded analyst estimates by 4.3%. Earnings per share (EPS) missed analyst estimates by 71%.
In the last 12 months, the only revenue segment was Gyre Pharmaceuticals contributing US$105.8m. The largest operating expense was Sales & Marketing costs, amounting to US$57.5m (64% of total expenses). Explore how GYRE's revenue and expenses shape its earnings.
Looking ahead, revenue is forecast to grow 42% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US.
Performance of the American Biotechs industry.
The company's shares are down 24% from a week ago.
Risk Analysis
We should say that we've discovered 2 warning signs for Gyre Therapeutics (1 shouldn't be ignored!) that you should be aware of before investing here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.